Over 90 researchers convened at the 4th TPD & Induced Proximity Symposium to discuss advancements in targeted protein degradation (TPD) and induced proximity. Key topics included chemoproteomics’ role in drug discovery and the integration of AI with mass spectrometry. The meeting underscored the growing community’s commitment to translating proteomic insights into therapeutic innovations.
Targeted protein degradation (TPD) is an emerging drug discovery strategy that offers an entirely different approach to tackle disease-relevant proteins, including classic “undruggable” targets. Instead of inhibiting protein function, small molecules like PROTACs and molecular glues co-opt the cell’s own ubiquitin-proteasome system to eliminate specific proteins altogether. But as this targeted approach gains traction, it also […]
In the webinar by Dr. Kristin Riching, the importance of real-time degradation kinetics in targeted protein degradation is highlighted. Kinetic data surpass traditional static assays by revealing crucial insights into degrader performance, aiding in drug design and optimization. Tools like the HiBiT tagging system simplify analysis, enhancing workflows in early discovery settings.
Targeted protein degradation (TPD) is a strategy used to selectively remove proteins from cells, rather than simply blocking their activity. Traditional small-molecule drugs work by binding to a protein and inhibiting its function, leaving the protein intact. In contrast, TPD harnesses the cell waste-disposal system—in particular, the ubiquitin-proteasome pathway—to tag the target protein for destruction. […]
For decades, the concept of “undruggable” targets has presented one of the most significant challenges in drug discovery. At our recent virtual event, Illuminating New Frontiers: Cracking the Undruggable Code, leading researchers and industry experts gathered to showcase cutting-edge technologies and fresh perspectives that are expanding the boundaries of therapeutic development. Over three engaging days, […]
Luminescent live-cell assays are powerful tools for cellular biology research. They offer both qualitative and quantitative insights into processes such as gene expression, cell viability, metabolic activity, protein and small molecule interactions, and targeted protein degradation. But what if you could go beyond the numbers and actually see what is happening in your cells? With […]
The third annual Targeted Protein Degradation (TPD) Symposium just wrapped up last month. It was kicked off with Poncho Meisenheimer, VP of Research and Development at Promega, likening the gathering of researchers to “kids in a biology candy store.” This playful analogy captured the vibrant energy and sense of exploration among the attendees, who convened […]
In the opening remarks of our second annual Targeted Protein Degradation Symposium, Tom Livelli, VP of Life Sciences Products & Services at Promega, posed a question to the attendees: “What do you want to be able to do today that you can’t?” This aspirational question set the tone for an event where building connections to […]
Monitoring and quantifying drug-target binding in a live-cell setting is important to bridging the gap between in vitro assay results and the phenotypic outcome, and therefore represents a crucial step in target validation and drug development (1). The NanoBRET™ Target Engagement (TE) assay is a biophysical technique that enables quantitative assessment of small molecule-target protein […]
“We are a company that is built upon innovation, and R&D is one of the main drivers of that,” says Frank Fan, Director of Biology at Promega. Promega Research and Development is focused on developing reliable tools that address the biggest problems facing life scientists. However, our R&D scientists do much more than just develop […]
